- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
MSD’s Cozaar ad claimed losartan was “as effective as other leading AIIAs” and quoted a Cochrane review. PMCPA found the presentation/quoting misleading…
Alcon challenged Allergan’s NHS retrospective cash rebate scheme for glaucoma drops as an inducement. The Panel initially found breaches, but the Appeal…
Anonymous GP alleged Lilly reps said long-acting exenatide would launch “within months”. Panel found complaint not proven on balance of probabilities; no…
A NiQuitin 21mg Clear Patch mailing used pharmacokinetic comparisons and “no other patch…” claims. Panel found misleading implied superiority/causal links and breaches…
Anonymous complaint upheld in part: Seretide materials referenced the MHRA (breach Clause 9.5 x2) and Avamys was described as “new” for over…
Norgine funded and coordinated a PR-led campaign that resulted in a Times letter opposing automatic generic substitution, but the published letter did…
Otsuka Europe was found in breach after a withdrawn advert appeared in an EPA programme and extensive congress materials (62/64 job bags)…
A UK employee ‘liked’ a global LinkedIn post calling Qutenza “highly effective”. The Panel said the ‘like’ disseminated promotion to the public…
A House of Commons diabetes summit flyer and APPG website content omitted Novo Nordisk’s sponsorship declaration. Verbal disclosure at the meeting wasn’t…
Ozempic leavepieces/iDetailer referenced CV benefits from SUSTAIN 6 but did not make the non-inferiority design and limits sufficiently clear. Breach of Clauses…
A Merz employee personally delivered Bocouture into the Republic of Ireland where it was unlicensed, to fix a shipping error. PMCPA found…
Ex-employee alleged Alcon promoted “BAK-free” Travatan before licence variation approval. Panel found pre-authorisation promotion and inadequate standards; breaches of Clauses 3.1, 9.1…
At a Parkinson’s congress, an invitation reached patients and an exhibition stand/website implied Azilect could slow progression. PMCPA found multiple breaches incl.…
Novo Nordisk’s NovoSeven leavepiece claimed cost‑effectiveness vs FEIBA using older efficacy inputs. PMCPA ruled the claim didn’t reflect the totality of evidence…
BMJ analysis suggested 1 Astellas due EUCTR trial lacked posted results. Astellas showed the trial was cancelled before recruitment, leaving no results…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.